Resistance Definitions developed from the NCI Breast Cancer Steering Committee (BCSC) Clinical Trials Planning Meeting (CTPM) - Next Generation Trials for Estrogen Receptor (ER)-positive Breast Cancer May 14-15, 2012

Primary Clinical Resistance
• **Adjuvant endocrine therapy**: Recurrence within the first 2 years of adjuvant endocrine therapy while on endocrine therapy
• **Metastatic endocrine therapy**: Progression within first 6 months of initiating first-line endocrine therapy while on endocrine therapy

Secondary Clinical Resistance
• **Adjuvant endocrine therapy**: Recurrence after more than 2 years of adjuvant endocrine therapy while on endocrine therapy (or within 12 months of completing adjuvant endocrine therapy), which may be further classified as early (between 2-5 years) or late (after 5 years)
• **Metastatic endocrine therapy**: Progression occurring 6 or more months after initiating endocrine therapy while on endocrine therapy